1 Min Read
* TAKEDA ANNOUNCES PUBLICATION OF FINAL DATA FROM ICLUSIG® (PONATINIB) PIVOTAL PHASE 2 PACE TRIAL IN BLOOD Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.